KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Retained Earnings: 2017-2024

Historic Retained Earnings for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to -$363.2 million.

  • Aquestive Therapeutics' Retained Earnings fell 19.93% to -$415.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$415.1 million, marking a year-over-year decrease of 19.93%. This contributed to the annual value of -$363.2 million for FY2024, which is 13.83% down from last year.
  • According to the latest figures from FY2024, Aquestive Therapeutics' Retained Earnings is -$363.2 million, which was down 13.83% from -$319.1 million recorded in FY2023.
  • In the past 5 years, Aquestive Therapeutics' Retained Earnings registered a high of -$186.3 million during FY2020, and its lowest value of -$363.2 million during FY2024.
  • Its 3-year average for Retained Earnings is -$331.2 million, with a median of -$319.1 million in 2023.
  • Data for Aquestive Therapeutics' Retained Earnings shows a maximum YoY plummeted of 42.75% (in 2020) over the last 5 years.
  • Aquestive Therapeutics' Retained Earnings (Yearly) stood at -$186.3 million in 2020, then tumbled by 37.87% to -$256.8 million in 2021, then declined by 21.19% to -$311.2 million in 2022, then decreased by 2.53% to -$319.1 million in 2023, then declined by 13.83% to -$363.2 million in 2024.